Fesoterodine

• Overactive Bladder
• Urinary Incontinence
• Urinary Urgency and Frequency
• Bladder Control Problems

Fesoterodine (Toviaz) is an extended-release antimuscarinic used to treat overactive bladder symptoms — urinary urgency, frequency, and urge incontinence. It is a prodrug that is rapidly converted in the bloodstream to 5-hydroxymethyl tolterodine (5-HMT), the same active metabolite produced by tolterodine, but with more predictable plasma levels because the conversion does not depend on the highly variable CYP2D6 enzyme. That pharmacokinetic advantage gives fesoterodine a more uniform dose-response across patients than its parent drug.

Mechanism of Action

Detrusor muscle contraction during bladder filling is mediated primarily by acetylcholine acting on M3 muscarinic receptors, with M2 receptors playing a modulatory role. In overactive bladder, involuntary detrusor contractions during the filling phase produce the sudden, often overwhelming urge that defines the condition; over time, those contractions can also lead to leakage, sleep disruption from nocturia, and quality-of-life impairment that drives many patients to restrict fluids or avoid leaving home.

Fesoterodine itself is pharmacologically inactive. Once absorbed, ubiquitous nonspecific plasma esterases hydrolyze it to 5-HMT, which competitively blocks M3 (and to a lesser extent M2) receptors on detrusor smooth muscle. This dampens involuntary contractions, increases functional bladder capacity, and reduces the number of urgency and incontinence episodes per day. Because conversion to the active metabolite does not rely on the CYP2D6 enzyme — which is highly variable across individuals due to genetic polymorphism — fesoterodine produces less interpatient variability in exposure than tolterodine. The MedlinePlus drug page summarizes patient-facing information, and the NIDDK overview of bladder control problems describes the underlying conditions.

Clinical Use

Fesoterodine is one option among several antimuscarinics for overactive bladder. Alternatives include oxybutynin, tolterodine, solifenacin, darifenacin, and trospium. Compared with immediate-release oxybutynin, the extended-release antimuscarinics — including fesoterodine — generally produce less dry mouth and less central nervous system penetration, which matters in older adults at risk for cognitive side effects.

For patients who do not tolerate antimuscarinic side effects or who have contraindications such as narrow-angle glaucoma or severe constipation, the beta-3 agonists mirabegron and vibegron are reasonable alternatives that avoid anticholinergic effects entirely. Combination therapy with a beta-3 agonist plus an antimuscarinic is sometimes used for refractory symptoms when monotherapy with either class is incomplete.

Across the antimuscarinic class, head-to-head comparative data show broadly similar efficacy with modest differences in side-effect profiles. Solifenacin and darifenacin are more M3-selective and may produce somewhat less central nervous system penetration; trospium is a quaternary amine that does not cross the blood-brain barrier and is therefore favored for patients with cognitive concerns; tolterodine and fesoterodine are similar in efficacy, with fesoterodine offering more predictable pharmacokinetics. Cost, formulary coverage, and prior individual response are the most useful drivers of choice among them.

First-line management of overactive bladder still emphasizes behavioral therapy — bladder training with progressively longer voiding intervals, scheduled voiding, fluid moderation (especially evening fluid restriction for nocturia), reduction of bladder irritants such as caffeine and alcohol, and pelvic-floor exercises. Pharmacologic therapy supplements rather than replaces those measures, and patients who skip behavioral work tend to have worse long-term outcomes regardless of medication.

For patients who fail oral therapy, third-line options include intradetrusor onabotulinumtoxinA injection, percutaneous tibial nerve stimulation, and sacral neuromodulation. Referral to urology or urogynecology is appropriate when symptoms persist despite optimized medical and behavioral therapy, when post-void residual is consistently elevated, or when there are red flags such as hematuria or recurrent infection that warrant further evaluation.

How to Take It

Fesoterodine is taken once daily, with or without food. Tablets must be swallowed whole and not crushed, split, or chewed because doing so disrupts the extended-release mechanism and produces a much higher peak concentration with worse side effects. Most patients start at 4 mg daily; if symptoms remain bothersome and the dose is well tolerated, the prescriber may increase to 8 mg after two to four weeks.

Dry mouth — the most common side effect — usually appears within the first few days. Sipping water, sugar-free gum, ice chips, and saliva substitutes help; patients on dry-mouth-prone medications should also pay extra attention to dental hygiene to mitigate the higher caries risk that comes with reduced salivary flow. Increasing dietary fiber, daily water intake, and gentle activity can mitigate constipation. Patients should expect about four to eight weeks of consistent use before judging full benefit, and should keep a brief voiding diary during that period to objectively assess response.

Monitoring and Follow-Up

Formal lab monitoring is not required. Follow-up at four to eight weeks should reassess voiding diary metrics — episodes of urgency, leakage, and nocturia — and screen for anticholinergic burden. In older adults, ask specifically about new confusion, falls, constipation, dry mouth severe enough to alter eating, and any vision changes. Periodic measurement of post-void residual urine volume is reasonable in patients with bladder outlet obstruction risk factors such as benign prostatic hyperplasia. Estimated glomerular filtration rate (from a basic metabolic panel — see understanding blood work and lab panels) guides dosing decisions, and intraocular pressure should be checked in patients at risk for narrow-angle glaucoma.

Special Populations

The maximum dose is 4 mg in patients with severe renal impairment (CrCl below 30 mL/min), in those taking strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, and in moderate hepatic impairment. Severe hepatic impairment is a contraindication. In elderly patients, the cumulative anticholinergic burden across all medications is the most important consideration — anticholinergic load has been linked to cognitive decline and dementia risk in observational studies, so the lowest effective dose, periodic deprescribing reviews, and preference for less-CNS-penetrant agents like trospium are appropriate. The American Geriatrics Society Beers Criteria flag the antimuscarinic class as potentially inappropriate in older adults precisely because of these concerns.

In warm weather — particularly relevant for our Florida patients — antimuscarinics can impair sweating and predispose to heat illness. Patients should take extra care during outdoor activity and consult our staying hydrated in Florida heat and heat exhaustion vs heat stroke guides for practical strategies.

Patient Counseling Pearls

Fluid management deserves more attention than it usually gets. Many patients with overactive bladder reflexively cut fluid intake to reduce symptoms, but severe restriction concentrates urine, which is itself a bladder irritant, and can cause dehydration, kidney stones, constipation, and falls in older adults. The reasonable target for most adults is roughly 1.5 to 2 liters of fluid spread evenly through the day, with the bulk consumed before mid-afternoon to reduce nocturia.

Caffeine, alcohol, carbonated beverages, citrus, and artificial sweeteners are common bladder irritants worth a structured trial of elimination. A two-week voiding diary before and after dietary changes often reveals what matters for an individual patient. Pelvic floor exercises remain underused and underprescribed; referral to a pelvic floor physical therapist is high-yield for many patients and is often covered by insurance.

Reducing nocturia — the most disruptive symptom for many patients — sometimes requires looking beyond the bladder. Untreated obstructive sleep apnea, lower-extremity edema from heart failure or venous insufficiency, evening diuretic timing, and excess evening fluid intake all contribute and respond to targeted intervention.

Drug Interactions

The most important interactions involve the strong CYP3A4 inhibitors that increase 5-HMT exposure: ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice. With any of these on board, the maximum fesoterodine dose is 4 mg. Combining fesoterodine with other anticholinergic medications — diphenhydramine, scopolamine, tricyclic antidepressants, certain antipsychotics, oxybutynin — produces additive dry mouth, constipation, urinary retention, and cognitive effects, and the cumulative anticholinergic burden warrants periodic deprescribing review.

When to Contact Your Doctor

Call promptly for inability to urinate, severe constipation lasting more than three days, vision changes or eye pain (which may indicate angle-closure glaucoma), new confusion or hallucinations, signs of heat illness (lightheadedness, hot dry skin, nausea), or facial swelling suggesting angioedema. New or worsening symptoms of urinary tract infection — burning, urgency that is qualitatively different from the chronic baseline, fever — should also prompt evaluation, as antimuscarinic-related elevated post-void residual can predispose to infection.

If you have questions about fesoterodine or your bladder symptoms, our team at Zimmer Medical Group can help — contact us or schedule a visit.